New Trial – Allogeneic Bone Marrow Mesenchymal Stem Cell Injection for Sarcopenia
The phase 1/2 trial plans to enroll 30 participants to assess CG-BM1’s safety and tolerability, with two doses administered one month apart.
Browse topics
Trials
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
The randomized, double-blind study will enroll about 150 patients to receive intravenous ALT001 at one of two doses or placebo, with functional change assessed at 24 weeks.
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
The UMC Utrecht-sponsored, randomized placebo-controlled study plans to enroll 162 infants with MRI-confirmed hypoxic-ischemic brain injury and assess motor development at 24 months.
New Trial – Autologous Lung Progenitor Cells for COPD
Regend Therapeutics plans a Phase 3, randomized, blinded, placebo-controlled study enrolling 102 people with COPD and emphysema to assess lung diffusion capacity at 52 weeks.
Trial – MesenCell Bone Marrow Stem Cells Evaluated in Chronic Graft-Versus-Host Disease
This Phase I, single-arm study plans to enroll 20 adults with steroid-refractory moderate or severe disease to receive up to three intravenous infusions alongside standard therapy.
Trial – Human Umbilical Cord Mesenchymal Stem Cell Injection Evaluated for Diabetic Nephropathy
Tongji Hospital is recruiting 15 participants for a single-center, dose-escalation Phase 1 study primarily assessing adverse events through 48 weeks after treatment.
Guts & Glory: Both of Cynata’s iPSC Trials Flop, GVH Phase 2 and KOA Phase 3
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of the trials.
Aspen Neuroscience Completes Cohort 3 and 4 Dosing in iPSC-Derived Phase 1/2a for Parkinson’s
The ASPIRO trial of sasineprocel is progressing; fifteen patients have been dosed with the commercial-ready formulation of the autologous cell therapy.
UniXell Biotechnology Nabs IND Clearance for its iPSC Parkinsons Therapy, UX-DA003
The Chinese company also received an IND in China a few weeks ago. Supported by good preclinical data, they'll advance clinical trials in both countries soon.
First Patient Dosed in Neural Stem Cell Therapy for Huntington’s Trial at UCI Health
The embryonic-derived cell therapy is implanted directly into the brain, and this early trial hopes to establish safety and baseline efficacy.
ElpasBio Completes Patient Enrollment in Phase III Trial of AlloJoin for Knee Osteoarthritis
This marks the first stem cell therapy for KOA to reach Phase III in China. The race is heating up...
Sana Biotechnology and Mayo Clinic Partner Up on Type 1 Diabetes Stem Cell-Derived Therapy, Phase 1 Potentially This Year
The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across care sites.
Cellenkos To Begin Phase 2 Cord Blood-Derived Treg Trial for Aplastic Anemia
Following their successful Phase 1, they've received clearance to begin Phase 2, where they'll assess whether it can reduce transfusion needs by calming the immune attack on bone marrow.
Cord for Life Completes Dosing of First Clinical Trial Using Cord Blood Stem Cells for Lower Back Pain
The Phase 1 cord blood-derived stem cell therapy for sacroiliac joint-related lower back pain showed an encouraging early safety profile and symptom improvement, supporting plans to begin Phase 2 later this year.
MEDIPOST’s Umbilical Cord Stem Cell Phase 3 For Knee Osteoarthritis Meets Primary Endpoints In Japan, Setting Up Commercialization
The trial demonstrated that Cartistem can both relieve symptoms and regenerate cartilage, and the company is advancing manufacturing readiness for its first overseas commercialization move.
Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway
Gallant said its pilot study found that intravenous stem cell therapy significantly improved pain and quality of life in cats with osteoarthritis versus placebo, supporting a faster regulatory route as the company pursues a disease-modifying treatment for an underserved condition.
XellSmart Launches iPSC Phase II for Parkinson’s Following Encouraging Phase I Results
The Phase II study will test XellSmart’s iPSC-derived off-the-shelf cell therapy in 30 Parkinson’s patients after Phase I showed meaningful motor and quality-of-life gains with no transplant-related adverse events.
Keck Medicine of USC Starting Parkinson’s Stem Cell Therapy Trial
Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s disease.
Aspen Neuroscience Begins Third Cohort in Parkinson’s Disease Stem Cell Therapy Trial with Commercial Formulation
Aspen’s trial advances with a commercial-ready, patient-derived cell therapy aiming to improve Parkinson’s outcomes and streamline clinical delivery.
BlueRock Therapeutics Begins Phase III Trial of Stem Cell Therapy for Parkinson’s Disease
The exPDite-2 trial will evaluate the safety and effectiveness of donor-derived stem cell therapy in Parkinson’s disease patients.
RBI Launching Phase 2 Brain Stem Cell Injection Trial for Alzheimer’s
The trial will inject autologous stem cells directly into the brain to bypass the blood-brain-barrier.
DoD-Funded Stem Cell Trial Expands to Phase II for Traumatic Brain Injury
A new clinical trial in Texas will evaluate stem cell therapy’s potential to improve outcomes for adults with chronic TBI.
New Trial: Umbilical Cord Stem Cell-Derived Exosome Nasal Drops for Neurodegenerative Diseases
Researchers will test whether nasal drops containing stem cell-derived vesicles can safely benefit people with a range of neurodegenerative diseases.
New Trial: Mesenchymal Stem Cell Exosomes for Preventing and Treating Organ Failure After Aortic Dissection Surgery
Researchers in China are testing whether exosomes can help prevent or treat organ failure after aortic dissection surgery.
Hope Biosciences Launches Phase Ib/IIa Stem Cell Trial for Early Alzheimer’s Disease
Hope Biosciences will study whether stem cell therapy can reduce inflammation or slow Alzheimer’s progression in a new clinical trial.